cabozantinib and Heart-Failure

The case report describes the presentation of incident heart failure with reduced ejection fraction, following Cabozantinib chemotherapy. In contrast to previous cases, despite maximal medical therapy for this gentleman it became irreversible and contributed to his death. Hence the case illustrates the potential cardiotoxicity of Cabozantinib and reinforces the need for co-ordinated multi-disciplinary team care for such patients. Within existing cardio-oncology infrastructure, it may mean that such patients require enhanced echocardiographic surveillance.

Topics: Anilides; Heart Failure; Humans; Neoplasms; Ventricular Dysfunction, Left

Cabozantinib is a multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factor receptor, as well as MET, RET, and AXL. It is currently approved for treating advanced thyroid and kidney cancers, and is being investigated in other cancers. We present a case of reversible heart failure due to cabozantinib use in a 70-year-old man with metastatic renal cell carcinoma. This is, to our knowledge, one of the first reported cases of cardiomyopathy associated with cabozantinib use.

Topics: Aged; Anilides; Carcinoma, Renal Cell; Heart Failure; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyridines; Ventricular Dysfunction, Left